{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:26:31Z","timestamp":1782782791712,"version":"3.54.5"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Duvelisib, a small-molecule phosphatidylinositol 3-kinase-\u03b4,\u03b3 inhibitor, has shown efficacy for mycosis fungoides (MF) at dosage ranges of 25-100 mg twice daily (BID), but with significant toxicity. We conducted a retrospective cohort study of patients with advanced MF treated with low-dose duvelisib (15 mg every other day to BID), in an effort to minimize toxicity. A total of 7 patients were included. The overall response rate on duvelisib was 71%, with the remaining patients maintaining stable disease. Mean modified Severity Weighted Assessment Tool score improved by 57.4% and mean percent body surface area involved improved by 52%. Median progression-free survival was 10.3 months. Adverse events occurred in 4 of 7 patients, the most common being fatigue (2\/7; grades 1-2), nausea (2\/7; grades 1-2), and transaminitis (2\/7; grade 3). Overall, low-dose duvelisib showed efficacy for advanced MF with less toxicity, providing a rationale for its use as monotherapy and potentially combinatorial therapy.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad345","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T05:18:57Z","timestamp":1705727937000},"page":"272-274","source":"Crossref","is-referenced-by-count":6,"title":["Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study"],"prefix":"10.1093","volume":"29","author":[{"given":"Christopher","family":"Bazewicz","sequence":"first","affiliation":[{"name":"Department of Dermatology, Penn State University , Hershey, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolena","family":"Verardi","sequence":"additional","affiliation":[{"name":"Cutaneous Lymphoma Program, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-5710","authenticated-orcid":false,"given":"Oleg","family":"Akilov","sequence":"additional","affiliation":[{"name":"Cutaneous Lymphoma Program, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"2024030500071930600_CIT0001","first-page":"55","article-title":"Cutaneous T-cell lymphoma: current and emerging therapies","volume-title":"Oncology (Williston Park)","author":"Dai","year":"2023"},{"key":"2024030500071930600_CIT0002","first-page":"1573","article-title":"Duvelisib for CLL\/SLL and follicular non-Hodgkin lymphoma","volume-title":"Blood","author":"Patel","year":"2019"},{"key":"2024030500071930600_CIT0003","first-page":"888","article-title":"Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume-title":"Blood","author":"Horwitz","year":"2018"},{"key":"2024030500071930600_CIT0004","first-page":"2598","article-title":"Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume-title":"J Clin Oncol","author":"Olsen","year":"2011"},{"key":"2024030500071930600_CIT0005","first-page":"1192","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume-title":"Lancet Oncol","author":"Kim","year":"2018"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/3\/272\/56831378\/oyad345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/3\/272\/56831378\/oyad345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:07:36Z","timestamp":1709597256000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/3\/272\/7577664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":5,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,18]]},"published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad345","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2024,1,18]]}}}